Evidence map›Paper›PMID 33117171›Full record

ArticleFrontiers in pharmacology2020

Transgenic

Megumi Yoshida, Ryodai Yamamiya, Yuto Shimizu, Kenjiro Yoshimura

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Megumi YoshidaDepartment of Machinery and Control Systems, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan.
Ryodai YamamiyaDepartment of Machinery and Control Systems, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan.
Yuto ShimizuDepartment of Machinery and Control Systems, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan.
Kenjiro YoshimuraDepartment of Machinery and Control Systems, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan.
Shibaura Institute of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transient receptor potential ankyrin 1 (TRPA1) channel is an ion channel whose gating is controlled by agonists, such as allyl isothiocyanate (AITC), and temperature. Since TRPA1 is associated with various disease symptoms and chemotherapeutic side effects, it is a frequent target of drug development. To facilitate the screening of TRPA1 agonists and antagonists, this study aimed to develop a simple bioassay for TRPA1 activity. To this end, transgenic

Indexed as

bioassaycell motilityChlamydomonas reinhardtiicilia and flagelladrug developmentphototaxisTRPA1TRP channel

Identifiers

PMID33117171
PMCPMC7550780
OpenAlexW3089815457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.